PITTSBURGH,
Feb. 23, 2015 /PRNewswire/
-- Mylan Specialty, the full integrated specialty
pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today
announced it will present new study results at the 2015 American
Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in
Houston. Three poster
presentations will include analyses of results from an exploratory,
cross-sectional, web-based survey of schools participating in the
EpiPen4Schools® program. A fourth poster presentation evaluates
epinephrine auto-injector design as it impacts human factors of
efficient drug delivery in children.
"Anaphylaxis is a serious and often unpredictable health
problem in the U.S., particularly among children and adolescents,"
said Roger D. Graham, President,
Mylan Specialty. "The
EpiPen4Schools® survey results provide
information regarding anaphylaxis management in schools, and it is
our hope that it contributes to the growing body of data related to
this important issue. There have been too many tragedies
reinforcing that when anaphylaxis occurs, every minute matters, and
immediate access to epinephrine and emergency medical care is
crucial. Mylan is committed to continuing our leadership role in
supporting those at increased risk for anaphylaxis in the school
setting and beyond. We are pleased to see legislative efforts
continue to enhance access to epinephrine, and we look forward to
supporting future efforts toward improved access, ultimately
advancing the understanding and management of
anaphylaxis."
The EpiPen4Schools® program, launched in
2012, provides four free EpiPen® or EpiPen
Jr® (epinephrine injection) Auto-Injectors to
qualifying* schools.
Presentations to be featured during the meeting
include:
-
EpiPen4Schools®
Survey
-
EpiPen4Schools®
Survey: Characteristics of Anaphylaxis and Common
Triggers
Poster 684, Feb. 23, 2015; 10:45-11:45
a.m. ET
Explores findings from a survey
of schools participating in the EpiPen4Schools®
program during the 2013-2014 school year to assess the
characteristics of anaphylactic events and associated allergic
triggers.
- Epinephrine Administration for Cases of Anaphylaxis in
a U.S. School Setting: Results From the
EpiPen4Schools®
Survey
Poster 685, Feb. 23, 2015; 10:45-11:45
a.m. ET
Reviews results from the survey
of reported anaphylactic events and treatment(s) administered at
each responding school during the 2013-2014 school
year.
- Occurrence of Anaphylaxis by School Grade Level and
Staff Training: Findings From the
EpiPen4Schools®
Survey
Poster 686, Feb. 23, 2015; 10:45-11:45
a.m. ET
Examines characteristics of
anaphylactic events – including grade level and frequency of
food-related triggers – and staff preparedness to respond to such
events in schools that participated in the program during the
2013-2014 school year.
- Designing Auto-Injectors for Children: Effect of Form
Factor on the Human Factors of Efficient Drug
Delivery
Poster 678; Feb. 23, 2015; 10:45-11:45
a.m. ET
Evaluates the design of three
different types of epinephrine auto-injectors
(cylindrical, elliptical and prismatic), against their
effect on human factors of efficient drug delivery (application
force, force angle and grip ergonomics) in
children.
Session details and full abstracts for the 2015 AAAAI
Annual Meeting can be found on the AAAAI meeting website at
http://annualmeeting.aaaai.org/.
*A school will only receive EpiPen®
Auto-Injectors in accordance with all applicable laws. The school
must submit a valid prescription in order to qualify for this
program. There is no requirement for a school to purchase
additional EpiPen® or EpiPen Jr®
Auto-Injectors or any other Mylan products.
Indications
EpiPen® (epinephrine injection) 0.3 mg and
EpiPen Jr® (epinephrine injection) 0.15 mg
Auto-Injectors are for the emergency treatment of life-threatening
allergic reactions (anaphylaxis) caused by allergens, exercise, or
unknown triggers; and for people who are at increased risk for
these reactions. EpiPen® and EpiPen
Jr® are intended for immediate
administration as emergency supportive therapy only. Seek immediate
emergency medical help right away.
Important Safety Information
EpiPen® and
EpiPen Jr® Auto-Injectors
contain a single dose of epinephrine, which you (or your caregiver
or others who may be in a position to administer
EpiPen® or EpiPen
Jr®) inject into the middle of your outer thigh
(upper leg) (through clothing, if necessary). Get emergency medical
help right away. You may need further medical attention. Only
a health care professional should give additional doses of
epinephrine if you need more than two injections for a single
anaphylactic episode. DO NOT INJECT INTO YOUR VEINS, BUTTOCKS,
FINGERS, TOES, HANDS OR FEET. In case of accidental injection,
please seek immediate medical treatment. Epinephrine should be used
with caution if you have heart disease or are taking certain
medicines that can cause heart-related (cardiac)
symptoms.
Tell your doctor if you have certain medical conditions
such as asthma, depression, thyroid disease, Parkinson's disease,
diabetes, high blood pressure or heart disease, have any other
medical conditions, are pregnant or plan to become pregnant, or are
breastfeeding or plan to breastfeed. Be sure to also tell your
doctor all the medicines you take, especially medicines for asthma.
If you have certain medical conditions, or take certain
medicines, your condition may get worse or you may have longer
lasting side effects when you use EpiPen®
or EpiPen Jr®.
The most common side effects may include increase in heart
rate, stronger or irregular heartbeat, sweating, nausea or
vomiting, difficulty breathing, paleness, dizziness, weakness,
shakiness, headache, apprehension, nervousness or anxiety. These
side effects may go away if you rest. Tell your health care
professional if you have any side effect that bothers you or that
does not go away.
Please see the full Prescribing Information
and Patient Information.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit
www.fda.gov/medwatch or call
1-800-FDA-1088.
For additional information, please contact us at
800-395-3376.
About Anaphylaxis
Anaphylaxis is a life-threatening allergic reaction that
has many possible triggers, occurs quickly, without warning, and
must be treated immediately with epinephrine. Symptoms
may include hives, swelling or redness of the skin, tightness in
the throat, nausea, dizziness, breathing problems, a decrease in
blood pressure and/or fainting. Anaphylaxis can be caused by
triggers, such as food, stinging and biting insects, medicines,
latex or even exercise. While symptoms of an allergic reaction vary
from person to person, reactions can quickly progress to become
life-threatening.
An epinephrine auto-injector, such as EpiPen®
Auto-Injector, should be given at the first sign of anaphylaxis,
followed by seeking immediate emergency medical care.
Antihistamines do not relieve the life-threatening symptoms of
anaphylaxis. Delays in epinephrine administration have been
associated with negative health consequences, even possibly
death.
About EpiPen® (epinephrine injection)
Auto-Injector
EpiPen® (epinephrine injection) and EpiPen
Jr® (epinephrine injection) Auto-Injectors are used
for the emergency treatment of life-threatening allergic reactions.
Each EpiPen 2-Pak® and EpiPen Jr
2-Pak® contains two single auto-injectors,
instructions for use and an EpiPen® Trainer, with no
drug or needle, to help patients become familiar
with the administration technique.
EpiPen® Auto-Injector should
be administered immediately at the first sign of an anaphylactic
reaction. EpiPen®
Auto-Injector is not a substitute for emergency medical
treatment. Patients should seek emergency medical attention
immediately following administration.
EpiPen® Auto-Injector has been
the No. 1 prescribed epinephrine auto-injector in the U.S. for more
than 25 years and has a simple, three-step administration process.
For more information about EpiPen®
Auto-Injector, please
visit www.EpiPen.com.
About Mylan Specialty
Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL),
is a specialty pharmaceutical company focused on the development,
manufacturing and marketing of prescription drug products for the
treatment of respiratory diseases, life-threatening allergic
reactions and psychiatric disorders. For more information, please
visit mylanspecialty.com.
About Mylan
Mylan is a global pharmaceutical company committed to
setting new standards in health care. Working together around the
world to provide 7 billion people access to high quality medicine,
we innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 25,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at
mylan.com
EpiPen®, EpiPen Jr®, EpiPen
2-Pak® and EpiPen Jr 2-Pak® are registered
trademarks of Mylan Inc. licensed exclusively to its wholly-owned
subsidiary, Mylan Specialty L.P.
EpiPen4Schools® is a
registered trademark of Mylan Inc.
© 2015 Mylan Specialty L.P. All rights
reserved.
EPI-2015-0121
Logo -
http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-specialty-to-present-findings-from-epipen4schools-program-survey-300039429.html
SOURCE Mylan Inc.